{"prompt": "['TABLE OF CONTENTS', 'SUMMARY OF CHANGES', 'i', 'AMC PROTOCOL SIGNATURE PAGE', '2', 'TABLE OF CONTENTS', '3', 'LIST OF TABLES AND FIGURES', '5', 'PROTOCOL ROSTER', '6', 'PROTOCOL SYNOPSIS', '7', 'PROTOCOL SCHEMA', '8', 'ABBREVIATIONS LIST', '9', '1.0', 'OBJECTIVES', '11', '1.1', 'Primary Objective', '11', '1.2', 'Secondary Objective', '11', '1.3', 'Exploratory Objective', '11', '2.0', 'BACKGROUND', '12', '2.1', 'Study Disease', '12', '2.2', 'Treatment Regimen', '12', '2.3', 'Study Design and Rationale', '12', '3.0', 'PARTICIPANT SELECTION', '14', '3.1', 'Eligibility Criteria', '14', '3.2', 'Exclusion Criteria', '15', '3.3', 'Number of Participants to be Enrolled', '16', '3.4', 'Participant Enrollment Procedures', '16', '4.0', 'TREATMENT PLAN', '17', '4.1', 'Treatment Administration', '17', '4.2', 'Concomitant Medication and Supportive Care Guidelines', '18', '4.3', 'Duration of Therapy', '19', '4.4', 'Duration of Follow Up', '20', '5.0', 'DOSING DELAYS/DOSE MODIFICATIONS', '21', '5.1', 'Dose Modifications for BV', '21', '5.2', 'Dose Modifications for Vincristine', '23', '5.3', 'Dose Modifications for Bleomycin', '24', '6.0', 'ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS', '26', '6.1', 'Adverse Events and Potential Risks Lists', '26', 'AMC-S007 (Version 2.0) 20MAR2018', '3', 'NCI Version Date 20MAR2018']['6.2', 'Classification of AEs by Severity and Relationship to Treatment', 'Administration', '26', '6.3', 'Expedited Adverse Event Reporting', '28', '6.4', 'Routine Adverse Event Reporting', '29', '6.5', 'Secondary Malignancy', '30', '6.6', 'Second Malignancy', '30', '7.0', 'PHARMACEUTICAL INFORMATION', '31', '7.1', 'Study Product Preparation', '31', '8.0', 'CLINICAL AND LABORATORY EVALUATIONS', '34', '8.1', 'Screening/Baseline Evaluations', '34', '8.2', 'Evaluations during Treatment', '34', '8.3', 'Treatment Discontinuation Evaluations', '35', '8.4', 'Final Evaluations, Off Study', '35', '9.0', 'MEASUREMENT OF EFFECT', '36', '9.1', 'Definition of Response', '36', '10.0', 'STATISTICAL CONSIDERATIONS', '39', '10.1', 'Study Design/Endpoints', '39', '10.2', 'Sample Size/Accrual Rate', '39', '11.0', 'ROLE OF DATA MANAGEMENT', '40', '11.1', 'CRF Instructions', '40', '11.2', 'Data Quality', '40', '11.3', 'Data Monitoring', '40', '12.0', 'ETHICAL AND REGULATORY CONSIDERATIONS', '41', '12.1', 'IRB Approval and Informed Consent', '41', '12.2', 'Changes to the Protocol', '41', '12.3', 'Women and Minorities', '41', '13.0 REFERENCES', '43', 'APPENDIX I: SCHEDULE OF EVALUATIONS', '44', 'APPENDIX II: PERFORMANCE STATUS SCALES', '45', 'APPENDIX III: AMC DATA AND SAFETY MONITORING PLAN', '46', 'APPENDIX IV: FACT-G QUESTIONNAIRE, VERSION 4, ENGLISH AND SWAHILI.49', 'AMC-S007 (Version 2.0) 20MAR2018', '4', 'NCI Version Date 20MAR2018']['LIST OF TABLES AND FIGURES', 'Table 4-A: Treatment Administration', '17', 'Table 5-A: Dose Modifications for BV - Nausea', '21', 'Table 5-B: Dose Modifications for BV - Vomiting', '21', 'Table 5-C: Dose Modifications for BV - Anemia', '22', 'Table 5-D: Dose Modifications for BV - Neutropenia', '22', 'Table 5-E: Dose Modifications for BV - Thrombocytopenia', '23', 'Table 5-F: Dose Modifications for Vincristine - Peripheral Neuropathy', '23', 'Table 5-G: Dose Modifications for Vincristine - Constipation or Ileus', '24', 'Table 5-H: Elevated Total Bilirubin', '24', 'Table 5-I: Dose Modifications for Bleomycin - Pulmonary Toxicity', '25', 'Table 5-J: Dose Modifications for Bleomycin - Renal Insufficiency', '25', 'Table 6-A: Adverse Event List for Vincristine', '26', 'Table 6-B: Adverse Event List for Bleomycin', '26', 'Table 6-C: Attribution', '28', 'Table 12-A: Accrual Targets', '42', 'AMC-S007 (Version 2.0) 20MAR2018', '5', 'NCI Version Date 20MAR2018']['PROTOCOL ROSTER', 'AMC Protocol #S007', 'Longitudinal Quality of Life Study Among Participants with AIDS-Associated Kaposi', 'Sarcoma at Bugando Medical Centre, in Mwanza, Tanzania', 'Protocol Chair:', 'Protocol Statistician:', 'Kristin Schroeder MD, MPH', 'Jeannette Y. Lee, PhD', 'AIDS Malignancy Consortium', 'AMC Statistical Center', 'P.O. Box 1370', 'University of Arkansas for Medical Sciences', 'Mwanza, Tanzania', '4301 W. Markham, #781', 'Tel: 255-686-3-86349', 'Little Rock, Arkansas 72205-7199', 'Email: kristin.schroeder@dm.duke.edu', 'Tel: (501)526-6712', 'Fax: (501) 526-6729', 'Email: JYLee@uams.edu', 'Protocol Co-Chair:', 'Data Management/Operations:', 'Nestory Masalu MD, MMed', 'AMC Operations and Data Management', 'Bugando Medical Centre', 'Center', 'P.O. Box 1370', 'The Emmes Corporation', 'Mwanza, Tanzania', '401 N. Washington Street, Suite 700', 'Tel: 255-783-0-00004', 'Rockville, MD 20850', 'Email: nmasaslu4@gmail.com', 'Tel: (301)251-1161', 'Fax: (240) 238-2842', 'Email: amipm@emmes.com', 'AMC Kaposi Sarcoma Working Group', 'Chair:', 'Lee Ratner, MD, PhD', 'Washington University School of Medicine', 'Division of Oncology', '660 S. Euclid Avenue', 'Campus Box 8069', 'St. Louis, MO 63110', 'Tel: 314-362-8836', 'Fax: 314-747-2120', 'Email: lratner@dom.wustl.edu', 'AMC-S007 (Version 2.0) 20MAR2018', '6', 'NCI Version Date 20MAR2018']", "completion": ""}